Trade commission bars imports of tirzepatide products that infringe Lilly's trademark
The order can stop infringing tirzepatide imports from any supplier, which may cut off some patients' supply of imported or compounded versions of the drug.
On April 9, 2025, the U.S. International Trade Commission issued a general exclusion order barring imports of products that contain, or claim to contain, tirzepatide and that infringe Eli Lilly's trademark or carry a false designation of origin [1]. The same action included cease and desist orders against three companies: Arctic Peptides, Triggered Brand and Strate Labs [1].
Tirzepatide is the active ingredient in Lilly's Mounjaro and Zepbound.
What the order covers
A general exclusion order is broader than one aimed at specific companies. It applies to any importer, not only the parties named in the case [1]. That means a product shipped by a company that was never part of the proceeding can still be stopped at the border if it falls within the order's terms [1].
The Commission's notice, published in the Federal Register on April 15, 2025, is titled "Certain Products Containing Tirzepatide and Products Purporting to Contain Tirzepatide" [1]. It addresses two categories of goods: products that actually contain tirzepatide, and products that merely claim to contain it [1].
The cease and desist orders direct Arctic Peptides, Triggered Brand and Strate Labs to stop the conduct at issue [1]. The exclusion order and the cease and desist orders are separate tools — one acts at the border, the other on the named companies.
What is not yet known
The order's effective date and the timetable for enforcement have not been reported [1]. It also has not been reported how border officials will identify covered shipments, whether the named companies have responded, or how the order treats products that are already inside the United States.
Another open question is how the order applies to compounding pharmacies. The order concerns importation, while compounded tirzepatide sold by U.S. pharmacies is typically made domestically. Whether the order reaches any part of that market has not been reported [1].
Why it matters for patients
Many people taking tirzepatide get it through a pharmacy rather than directly from the manufacturer. If a supplier's product is imported and falls under the order, that supply can be stopped at the border with little warning.
The order is aimed at infringing imports, not at Lilly's own FDA-approved tirzepatide products. So it does not change the status of Mounjaro or Zepbound, and it does not create new supply anywhere.
The "purporting to contain" language points to a separate concern. A product that claims to contain tirzepatide but does not can leave a patient paying for a drug they are not actually getting [1]. That is a labeling question as much as a legal one.
Cost and access are part of the picture, too. Imported and compounded versions are often priced below brand-name products, and a supply interruption can force a change in what a patient is taking and what they pay. The order does not address price or coverage, and it does not set out any alternative source of the medication.
What happens next
The notice was published in the Federal Register on April 15, 2025 [1]. Enforcement at the border is the practical next step. The date the order takes effect, and whether any period of review applies before it does, have not been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.